Clinical Analysis of Endometriosis Treatment Using Mifepristone
article
OA: closed
CC0
⤵ 1 in-corpus citation
AI-generated summary
Low-dose mifepristone treatment in postoperative endometriosis patients improved symptoms and endometrial hyperplasia with minimal endocrine impact and fewer side effects compared to a higher dose.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Objective: To investigate the clinical effects of mifepristone with different dosage in postoperative patients with endometriosis, and observe the influences of mifepristone on endocrine function. Methods: 27 cases suffered conservative surgeries for pelvic endometriosis were randomly divided into 3 groups: observation group 1 (10 cases, with the administration of 6.25 mg/d mifepristone); observation group 2 (10 cases, 12.5 mg/d mifepristone); and the control group (7 cases, regular follow-up with no medication). The 20 subjects of observation groups 1 and 2 were administered mifepristone within 5 days during the first menstrual period postoperation, with a therapy course of 6 months. The clinical effects, adverse reactions, and the influences on endocrine functi on of mifepristone with different dosage were compared. Results: The menorrhalgia symptoms were relieved in these 3 groups. The incidence of nausea in the observation group 1 (30%) were obviously lower than the group 2 (60% ). The changes of serum levels of sex hormones in the observation group 1 were not significant, while the progesterone levels in group 2 degraded obviously (P 0.05). Conclusions: Low dose mifepristone can be applied in the postoperative consolidation therapy for pelvic endometriosis for its safety, utility, few adverse effects, little influences on endocrine function, and the improvement of endometrial hyperplasia.
My notes (saved in your browser only)
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (1)
Cited by (1)
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK